Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Joly

Showing results (261-270 of 336) with videos related to

Pageof 34
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 14, 2015
How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI studyJulie Vanbockstael, Elodie Coquan, Sophie Gouerant, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 29, 2025
Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancerSharon H Nahm, Belinda E Kiely, Rachel L O'Connell, et al.
Gynecologic Oncology|February 6, 2022
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO studyFlorence Joly, Michel Fabbro, Philippe Follana, et al.
Breast (Edinburgh, Scotland)|April 29, 2020
Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical studyAntonio Di Meglio, Stefan Michiels, Lee W Jones, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 3, 2020
Cognitive Impairment in Patients with Breast Cancer before Surgery: Results from a CANTO Cohort SubgroupMarie Lange, Isabelle Hardy-Léger, Idlir Licaj, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 6, 2023
Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinomaLucie Thorel, Pierre-Marie Morice, Hippolyte Paysant, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 28, 2022
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit StudyYeh Chen Lee, Madeleine T King, Rachel L O'Connell, et al.
Bulletin Du Cancer|March 17, 2018
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]Marianne Lorcet, Alain Lortholary, Jean Emmanuel Kurtz, et al.
Trials|March 5, 2022
A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study designAntonio Di Meglio, Elise Martin, Tracy E Crane, et al.
Nature Communications|July 16, 2024
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trialIsabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, et al.
Pageof 34

Showing results (261-270 of 336) with videos related to

Sort By:
Pageof 34
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 14, 2015
How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI studyJulie Vanbockstael, Elodie Coquan, Sophie Gouerant, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 29, 2025
Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancerSharon H Nahm, Belinda E Kiely, Rachel L O'Connell, et al.
Gynecologic Oncology|February 6, 2022
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO studyFlorence Joly, Michel Fabbro, Philippe Follana, et al.
Breast (Edinburgh, Scotland)|April 29, 2020
Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical studyAntonio Di Meglio, Stefan Michiels, Lee W Jones, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 3, 2020
Cognitive Impairment in Patients with Breast Cancer before Surgery: Results from a CANTO Cohort SubgroupMarie Lange, Isabelle Hardy-Léger, Idlir Licaj, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 6, 2023
Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinomaLucie Thorel, Pierre-Marie Morice, Hippolyte Paysant, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 28, 2022
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit StudyYeh Chen Lee, Madeleine T King, Rachel L O'Connell, et al.
Bulletin Du Cancer|March 17, 2018
[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey]Marianne Lorcet, Alain Lortholary, Jean Emmanuel Kurtz, et al.
Trials|March 5, 2022
A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study designAntonio Di Meglio, Elise Martin, Tracy E Crane, et al.
Nature Communications|July 16, 2024
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trialIsabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, et al.
Pageof 34